"I am excited to join Avalo's Board at this pivotal stage in the company's growth, with the progressing Phase 2 LOTUS trial in HS expected to readout in the middle of next year," said Dr. Jain. "I was drawn to this opportunity given AVTX-009's proven mechanism of action, its potential to become a best-in-disease treatment in HS, and its potential in addressing unmet needs in a number of additional large inflammatory diseases. With my experience in navigating strategic growth in immunology and inflammation a ...